1 Abourashed E, El-Alfy A, Khan I, et al. Ephedra in perspective - a current review. Phytotherapy Research 2003; 17:703-712.
AHPA, 2000. Ephedra Survey Results: 1995-1999. Survey Administered & Results Compiled by: Arthur Andersen LLP
2 prepared for The American Herbal Products Association (April 28, 2000).
Alanko K, Kanerva L, Mohell-Talolahti B, Jolanki R and Estlander T. Nonpigmented fixed drug eruption from
3 pseudoephedrine. J Am Acad Dermatol 1996; 35:647-648.
Allison DB, Fontaine KR, Manson JE, et al. Annual deaths attributable to obesity in the United States. JAMA 1999;
4 282(16):1530-8.
Alvarez-Requejo A, Carvajal A, Begaud B, et al. Under-reporting of adverse drug reactions. Estimate based on a spontaneous
5 reporting scheme and a sentinel system. Eur J Clin Pharmacol 1998; 54:483-8.
6 American Stroke Assocation, American Heart Association. Heart Disease and Stroke Statistics: 2003 Update 2003.
7 Anibarro B and Seoane FJ. Nonpigmenting fixed exanthema induced by pseudoephedrine. Allergy 1998; 53:902-903.
Armstrong, W.J., Johnson, P. and Duhme, S. The effect of commercial thermogenic weight loss supplement on body
8 composition and energy expenditure in obese adults. Journal of Exercise Physiology May 2001; 4:28-35.
Ashar B, Miller R, Getz K, et al. A critical evaluation of internet marketing of products that contain ephedra. Mayo Clin Proc
9 2003; 78:944-46.
Astrup A., et al. Thermogenic, metabolic, and cardiovascular effects of a sympathomimetic agent, ephedrine, a double-blind
10 placebo-controlled study. Current Therapeutic Research Dec 1990; 48:1087-1100.
Astrup A.: Video testimony for the USDHS Public Hearing: Safety of dietary supplements containing ephedrine alkaloids.
11 (Aug. 8-9, 2000).
Austin DF, Werner SB. Epidemiology for the health sciences: a primer on epidemiologic concepts and their uses. Charles C.
12 Thomas Publishers, Springfield, IL, 1974.
Ayorinde BT, Buczkowski P, Brown J, et al. Evaluation of pre-emptive intramuscular phenylephrine and ephedrine for
13 reduction of spinal anaesthesia-induced hypotension during caesarean section. Br J Anaesth 2001; 86:372-376.
Bailes J, Cantu R, Day A. The Neurosurgeon in sports: awareness of the risks of heatstroke and dietary supplements.
14 Neurosurgery 2002; 51:283-88.
Balyeat RM, Rinkel HJ. Clinical notes, suggestions and new instruments: Urinary retention due to the use of ephedrine.
15 JAMA 1932; 98:1545-1546.
Banner AS, Sunderrajan EV, et al. Arrhythmogenic effects of orally administered bronchodilators. Arch. Intern. Med Apr
16 1979; 139:434-437.

17	Baselt R. and Cravey, R. (1995). Ephedrine. Disposition of Toxic Drugs and Chemicals in Man. 4th ed. Pp.290-291. Chemical Toxicology Institute, Foster City, California.
18	Baum C, Anello C. The Spontaneous Reporting System in the United States. In: Strom BL, editor. Pharmacoepidemiology. Second ed. New York, NY:John Wiley & Sons, 1994:107-118.
19	Beckett AH, Wilkinson GR. Urinary excretion of (-)-methylephedrine, (-)-ephedrine and (-)-norephedrine in man. J Pharm Pharmacol 1965; 17:107S-108S
20	Bell DG, Jacobs I. Combined caffeine and ephedrine ingestion improves run times of Canadian Forces warrior test. Aviat. Space Environ Med. 1999; 70:325-329.
21	Bell DG, Mclellan TM, Sebiston CM. Effect of ingesting caffeine and ephedrine on 10-km run performance. Med Sci Sports Exercise Feb 2002; 344-349.
22	Billings C, Ralston R, Hare D. Untoward effects of a syrnpathomimetic amine, Aerospace Medicine 1974; 45,551-2
23	Blanck HM, Khan LK, Serdula MK. Use of nonprescription weight loss products: results from a multistate survey. JAMA. 2001;286(8):930-5.
24	Blendon, R.J., DesRoches C, Benson J, et al. Americans' views on the use and regulation of dietary supplements. Arch Intern Med 2001;161:805-810
25	Blumberg M, Tinkelman DG, et al. Terbutaline and ephedrine in asthmatic children. Pediatrics Jul 1977; 60(1):14-19.
26	Bondereva, T.S., Young R and Glennon RA. Central stimulants as discriminative stimuli: Asymmetric generalization between (-)-ephedrine and S(+)-methamphetamine. Pharmacol. Biochem. Behav 2002; 74: 157-162.
27	Boozer CN, Homel P, Daly P. Letter to Charles W. Prettyman re: response to the special government expert reviews of the Boozer-Daly study. October 21, 2003.
28	Boozer CN. Letter to Patricia Beaston, Norman Kaplan, Richard Atkinson, and Mark Espeland re: response to special government expert reviews of the Boozer-Daly study. October 22, 2003.
28a	Boozer CN. Letter to Mark B McClellan. July 24, 2003.
29	Boozer CN, Daly P, Solomon J, et al: Herbal ephedrine/caffeine for weight loss : A 6-month trial. FASEB Journal 2001; 15(4):A403.
30	Bowers LD. Abuse of performance-enhancing drugs in sport. Ther Drug Monit 2002; 24(1):178-81.
31	Bravo E. Phenylpropanolamine and other over-the-counter vasoactive compounds. Hypertension 1998; 11 (2 Suppl 3):7-10.
32	Bray GA. Low carbohydrate diets and the realities of weight-loss JAMA 2003;289:1853-55 (2003).

33 Brown RD, Whisnant JP, Sicks JD, et al. Stroke incidence,prevalence, and survival: secular trends in Rochester, Minnesota, through 1989. Stroke 1996:27:373-80.

34 Burnham TH, Novak KK, Bell WL, et al. Ephedrine. In: Drug Facts and Comparisons. St Louis, MO: Facts and Comparisons; 2002. p. 692 (updated).

35 Bush RK, Smith A, Welling P, et al. A comparison of a theophylline-ephedrine combination with terbutaline. Annals of Allergy1978; 41:13-17.

36 Camisa C. Fixed drug eruption due to pseudoephedrine. Cutis 1988; 41:339-340.

37 Catlin DH, Sekera M, Adelman DC. Erythroderma associated with ingestion of an herbal product. West J Med 1993; 159:491-493.

38 Catlin DH, Murray TH. Performance-enhancing drugs, fair competition, and Olympic sport. JAMA 1996;276(3):231-7.

39 Cavanah DK, Ballas ZK. Pseudoephedrine reaction presenting as recurrent toxic shock syndrome. Ann Intern Med 1993; 119:302-303.

40 Centers for Disease Control and Prevention. Obesity Epidemic Increases Dramatically in the United States. available at URL: http://www.cdc.gov/nccdphp/dnpa/obesity-epidemic.htm. Accessed 6/11/2002.

41 Chase SL. Ephedra is linked to CNS, cardiovascular risks. RN 2001;64(2):103.

42 Chen C, Biller J, Willing S, et al. Ischemic stroke after using over the counter products containing ephedra. Journal of the Neurological Sciences 2004; 217:55-60.

43 Chen KK. The effect of repeated administration of ephedrine. J Pharmacol Exper Therapeut 1926b; 27:77-86.

44 Chopra RN and Mukherjee B (1933). Toxic effects of ephedrine - A warning. The Indian Medical Gazette Nov 1933;622-626.

45 Chua SS, Benrimoj SI, Gordon RD, et al. A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients. Br J Clin Pharmacol 1989; 28:369-372.

46 Chuang-Stein C. The role and analysis of benefit and risk in the development of new drugs. In: The benefit/risk ratio: a handbook for the rational use of potentially hazardous drugs, Korting HC, Schafer-Korting M, Eds. 1999. Boca Raton, FL, CRC Press LLC, pp. 1-10.

47 Clark R, Curry S. Pseudoephedrine dangers. Pediatrics 1990; 85(3):389-390.

48 Cohen, B. The cardiorespiratory effects of oral terbualine and an ephedrine-theophylline-phenobarbital combination: comparison in patients with chronic obstructive ventilatory disorders. Annals of Allergy Apr 1978 40:233-239.

49	Colker CM, Torina G, Swain M, et al. Double-blind, placebo controlled evaluation of the safety and efficacy of ephedra, caffeine, and salicin for short term weight reduction in overweight subjects. American Society of Exercise Physiologists 2nd Annual Meeting 1999, Abstract 26.
50	Colditz GA. Economic costs of obesity and inactivity. Med Sci Sports Exerc. 1999;31(11 suppl):S663-7
51	Colker CM, Swain MA, Lynch L. A pilot study evaluating the effects of an ephedrine and forskolin-based product on body weight and body composition in overweight, healthy women. J Am Coll Nutr. 2001;20(5):a98(Abstract).
52	CRN 2003. CRN praises FDA analysis on ephedra; criticizes an article used in analysis. (March 7, 2003).
53	Curtis, B., et.al. Autonomic Tone as a Cardiovascular Risk Factor: The Dangers of Chronic Fight or Flight. Mayo Clin Proc. 2002;77:45-54.
54	Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med 1995; 12:49-51.
55	DeMatteis, R., Arch, JR, Petroni, et al. Immunohistochemical identification of the beta adrenoceptor in intact human adipocytes and ventricular myocardium: effect of obesity and treatment with ephedrine and caffeine. Int J Obes Relat Metab Disord Nov 2002; 1442-1450.
56	DHHS (Department of Health and Human Services). Task force on health risk assessment. Determining risks to health: Federal policy and practice. 1986. Washington, DC, DHHS, pp. 8-24.
57	DHHS (Department of Health and Human Services). Analysis of Redacted Information in Metabolife Ephedra Call Records. January 23, 2004. Office of Science and Data Policy, Office of the Assistant Secretary for Planning and Evaluation. Washington, DC.
58	Dowd J, Bailey D, Moussa K, Nair S, et al. Ischemic colitis associated with pseudoephedrine: four cases. Am J Gastroenterol 1999; 94:2430-2434.
59	Doyon, S. The many faces of ecstasy, Current Opinion in Pediatrics 2001, 13, 170-176
60	Evans WC. "Trease and Evans' Pharmacognosy," London: WB Saunders (1989).
61	Evans E, Miller DS. The effect of ephedrine on the oxygen consumption of fed and fasted subjects. Proc Nutritional Society 1977; 36:136A.
62	Falkebom M, Persson I, Terent A, et al. Long-term trends in incidence of and mortality from acute myocardial infarction and stroke in women: Analyses of total first events and of deaths in the Uppsala Health Care Region, Sweden. Epidemiology 1996;7:67-74.
63	Falliers CJ, Cato AE, Harris J. Controlled assessment of oral bronchodilatos for asthmatic children. J Int Med Res 1978; 6:326-336.

63a	FDA. Letter to Carol N. Boozer, Director Energy Metabolism Core Laboratory. February 4, 2004.
63b	FDA. Letter to A. Wes Siegner Jr., Hyman Phelps & McNamara, P.C. February 4, 2004.
64	FDA. Memorandum: Articles rejected from RAND efficacy analysis. Lori Love, Office of Regulatory Affairs. February 3, 2004.
65	FDA. Memorandum: CAERS adverse event reports related to ephedra and Metabolife (January 1994-January 2004). (January 29, 2004).
66	FDA. 1995 Health Hazard Evaluation Board, CFSAN. HHEB No. 3460. Adverse health reactions occurring with the use of Nature's Nutrition Formula One.
67	Fernas R, Heckert J. Substances are easily obtained. Los Angeles Times. Aug. 11, 2001; Sect: Sports.
68	Flegal KN, Carroll MD, Ogden CL et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002; 288:1723-1727.
69	Fletcher AP. An appraisal of spontaneous adverse event monitoring. Adverse Drug Reactions & Toxicological Reviews 1992;11:213-27.
70	Fletcher AP. Spontaneous adverse drug reaction reporting vs event monitoring: a comparison. Journal of the Royal Society of Medicine 1991;84:341-4.
71	Flood V, Webb K, Lazarus R, Pang G. Use of self-report to monitor overweight and obesity in populations: some issues for consideration. Aust N Z J Public Health 2000;24:96-9.
72	Fong H. Ephedra-containing compounds: Historical and pharmacologic context. Hearings Before the US Public Health Service (Aug. 8, 2000).
73	Fontaine, K.R., Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA 2003;289:187-193.
74	Fontanarosa PB, Rennie D, et al. The need for regulation of dietary supplements--lessons from ephedra. JAMA 2003; 289:1568-1570.
75	Franklin QJ. Sudden death after typhoid and Japanese encephalitis vaccination in a young male taking pseudoephedrine. Mil Med 1999; 164:157-159.
76	Freudenberg W, Rogers EF. New alkaloids in aconitum napellus. J Am Chem Soc 1937; 59:2572-75.
77	Fujioka K, Seaton TB, Rowe E, et al. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2000;2(3):175-87.
78	Galuska DA, Will JC, Serdula MK, Ford ES. Are health care professionals advising obese patients to lose weight? JAMA. 1999;282(16):1576-8.

79	Gardner S, Franks A, Gurley B, et al. Effect of a multicomponent, ephedra-containing dietary supplement (Metabolife 356) on holter monitoring and hemostatic parameters in healthy volunteers. American Journal of Cardiology 2003; 91:1510-13.
80	General Practitioner Research Group. An antihistamine-sympathomimetic combination in the treatment of hayfever. The Practioner June 1981; 225:929-931.
81	Geumei A, Miller WF. New Oral Bronchodilator Drug with Relatively Selective Stimulation of Beta2-Adrenergic Receptors Chest 1977; 72(3):267-68.
82	Geumei A, Miller WF, Paez P, et al. Evaluation of a New Oral beta2-Adrenoceptor Stimulant Bronchodilator, Terbutaline. Pharmacology 1975 13:201-211.
83	Gill N, Shield A, Blazevich A, et al. Muscular and cardiorespiratory effects of pseudoephedrine in human athletes. Br Clin Pharmacol 2000; 50:205-13.
84	Gokcel A, Karakose H, Ertorer EM, et al. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001;24(11):1957-60.
85	Goldstein et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation Jan 2001:103(1):163-82
86	Goodman and Gilman's The Pharmacological Basis of Therapeutics. Tenth Edition 2001
87	Gorey JD, Wahlqvist ML, Boyce NW. Adverse reaction to a Chinese herbal remedy. Med J of Aust 1992; 157:484-486.
88	Greenway FL, Raum WJ, DeLany JP. The effect of an herbal dietary supplement containing ephedrine and caffeine in oxygen consumption in humans. The Journal of Alternative and Complementary Medicine 2000; 6:553-55.
89	Greenway FL. The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent. Obes Rev Mar 2001; 2:199-21, 2001
90	Gregg EW, Gerzoff RB, et al. Intentional weight loss and death in oversight and obese U.S. adults 35 years of age and older. Ann Int Med Mar 2003; 138:383-390.
91	Gulland JM, Virden CJ. Physiologically active constituents of the Yew, Taxus baccata. Part II. Ephedrine. J Chem Soc 1931:2148-2151.
92	Gurley BJ, Gardner SF, Hubbard MA. Content versus label claims in ephedra-containing dietary supplements. Am J Healthy Syst Pharm May 15, 2000; 57:963-69.
93	Hall PA, Bennett A, Wilkes MP, et al. Spinal anesthesia for caesarean section: comparison of infusions of phenylephrine and ephedrine. Br J Anaesth 1994; 73: 471-474.
94	Haller CA, Benowitz NL. Letter to the Editor of the N Eng J Med., N Eng J Med, April 5, 2001. 344(14):1096-1097.

95	Hardman, J.G.; Limbird, L.E. Goodman and Gilman's Pharmacological Basis of Therapeutics. 9th ed. New York: McGraw-Hill, Health Professions Division, c1996, 221-4
96	Harnack LJ, Rydell SA, Stang J. Prevalence of use of herbal products by adults in the Minneapolis/St Paul, Minn, metropolitan area. Mayo Clin Proc. 2001;76(7):688-94.
97	Hauken M. Fixed drug eruption and pseudoephedrine. Ann Intern Med 1994; 120:442-442.
98	Heller RF, Chinn S, Pedoe HD, et al. How well can we predict coronary heart disease? Findings in the United Kingdom Heart Disease Prevention Project. Br Med J (Clin Res Ed) May 12, 1988; 288(6428):1409-11.
99	Henney, J.E. 1999. Statement by Jane E. Henney, M.D., Commissioner, Food and Drug Administration, Department of Health and Human Services Before the Committee on Government Reform, March 25, 1999. U.S. House of Representatives, Washington, DC. [http://www.fda.gov/ola/1999/dietary.html].
100	Hensrud DD, Engle DD, Scheitel SM. Underreporting the use of dietary supplements and nonprescription medications among patients undergoing a periodic health examination. Mayo Clin Proc 1999;74:443-7.
101	Herbst AI, Hubby MM, Azizi F, et al. Reproductive and gynecologic surgical experience in diethylstilbestrol-exposed daughters. Am J Obstet Gynecol 1981;141:1019-28.
102	Heydon J, Pillans P. Allergic reaction to pseudoephedrine [letter]. N Z Med J 1995; 108:112-l 13.
103	Hill JO, Hauptman J, Anderson JW, Fujioka K, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;. 69:1108-16.
104	Hindioglu U, Sahin S. Nonpigmenting solitary fixed drug eruption caused by pseudoephedrine hydrochloride. J Am Acad Dermatol 1998; 38:499-500.
105	Hoffman BB and Lefkowitz RJ (1990). Catecholamines and sympathomimetic drugs. In:Goodman and Gilman's The Pharmacological Basis of Therapeutics, Gilman AG, Rail TW, Nies AS, Taylor P: (eds), New York, McGraw-Hill, Inc., 187-220.
106	Hu, S. 2000. Botanical, Agricultural, Production, and Supply Aspects of Ephedra. Unpublished.
107	Huber, G.L. 1999. The benefits and risks of dietary supplements in the practice of bariatric medicine and weight management. Presented at the Ephedra International Symposium, American Herbal Products Association, Pentagon City-Arlington, VA. December 9-10, 1999. Unpublished.
108	Huber, G.L. 2000. Study on Dietary Supplements for Weight Loss. Presented at the Office on Women's Health, U.S. Department of Health and Human Services (HHS) public meeting on the safety of dietary supplements containing ephedrine alkaloids, in Washington, D.C., on August 8-9, 2000. Unpublished.

109	Hutchins GM. Ma huang toxicity. Mayo Clinic Proceedings 2002; 77(7):733. [http://www.mayo.edu/proceedings/2002/jul/7707le.pdf].
110	Huxtable RJ. The myth of beneficent nature: The risks of herbal preparations. Ann Intern Med 1992; 117:165-166.
111	ICH Steering Committee. 1996. Guideline for Good Clinical Practice (ICH Harmonised Tripartite Guideline). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceutical for Human Use (ICH), No. E6.
112	Jequier.E., Munger R, Felber JP. Thermogenic effects of various beta-adrenoceptor agonists in humans: their potential usefulness in the treatment of obesity. Am. J. Clin. Nutr 1992; 55:249S-251S.
113	JESC/ACC (Joint European Society of Cardiology/American College of Cardiology). Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000;36:959-69.
114	Johannes CB, Crawford SL, McKinlay JB. Interviewer effects in a cohort study: results from the Massachusetts Women's Health Study. Am J Epidemiol 1997;146:429-38.
115	Jones D, Egger T. Use of herbs containing natural source ephedrine alkaloids in weight loss programmes. Int J Obes 1993; 17 (Suppl. l):S81.
116	Kajimura K, Iwamoto Y, Yamasaki K., et al. Variation of growth and contents of ephedrine type alkaloids in *Ephedra distachya* . Natural Medicines 1994;48:122-125.
117	Kalman D, Incledon T, Gaunaurd I, et al. An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra-caffeine weight loss product in health overweight adults. International Journal of Obesity 2002; 26:1363-66.
118	Kanai T, Nishikawa T, Satoh A, et al. Cardiovascular teratogenicity of ephedrine in rats. Teratology 1986b; 34(3):246 (Abstract).
119	Kanayama G, Gruber AJ, Pope HG Jr., et al. Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem? Psychother Psychosom 2001; 70(3):137-40.
120	Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes 2000; 24(12):1567-72.
121	Kennedy J. "Dietary supplement use in US army special operations candidates. Military Medicine 1999; 164(7):495-501.
122	Kennedy DL, Goldman SA, Lillie RB. Spontaneous reporting in the United States. In: Strom BL. Pharmacoepidemiology, 3rd Edition. 2000. New York, John Wiley & Sons, p. 166.
123	Krivda SJ, Benson PM. Nonpigmenting fixed drug eruption. J Acad Dermatol 1994; 31:291-292.

124	Lai CM, Stoll RG, Look ZM, et al. Urinary excretion of chlorpheniramine and pseudoephedrine in humans. J Pharm Sci 1979; 68:1243-1246.
125	Lake OA, Slijkhuis C, Maas WF, et al. Quality and safety of products containing Ephedra Herba on the Dutch market. National Institute of Public Health and the Environment (RIVM) Report 670220001 (2001).
126	Lang T, Ducimetiere P, Arveiler D, et al. Incidence, case fatality, risk factors of acute coronary heart disease and occupational categories in men aged 30-59 in France. Int J Epidemiol 1997; 26:47-57.
127	Lefkowitz RJ, Hoffman BB, Taylor P. 1990. Neurohumoral transmission: The autonomic and somatic motor nervous systems. In: Gilman, A.G., Rall, T.W., Nies, A.S., and Taylor, P. (Eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics (8th Ed.). Pergamon Press Ltd., New York, NY, Toronto, ON, pp. 89-90.
128	Lerman BB, Benardinelli L, West GA, et al. Adenosine-sensitive ventricular tachycardia: evidence suggesting cyclic AMP-mediated triggered activity. Circulation 1986;74:270-280.
129	Lewis JD, Strom BL. Balancing safety of dietary supplements with the free market. Ann Int Med 2002; 136: 616-618.
130	Lichtenstein, G,; Yee, N. Ischemic colitis associated with decongestant use. Annals of Internal Medicine 2000; 132:682.
131	Litovitz TL, Klein-Schwartz W, Rogers G, et al. 2001 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002; 20:391-452.
132	Love LA. Evaluation of adverse event reports with the use of ephedrine alkaloid-containing dietary supplements, June 1, 1997 - March 31, 1999. Hearings Before the US Public Health Service (Aug. 8, 2000).
133	Malchow-Moller A, Larsen S, Hey H, et al. Effect of Elsinore tablets in the treatment of obesity. A controlled clinical investigation. Ugeskrift for Laeger 1980; 142:1496-1499.
134	Manaligod LM, Gavani UD, Hyde J et al. Safety and effectiveness of terbutaline in children with chronic asthma. Chest 1979; 76:532-535.
135	Mann RD. Prescription-event monitoring. In: Strom BL. Pharmacoepidemiology, 3rd Edition. 2000. New York, John Wiley & Sons, pp. 231-46.
136	Marcus, D.M., Grollman A.P. Botanical Medicines – The need for new regulations. N Engl J Med 2002; 347:2073-2076.
137	Mariani P (1986). Pseudoephedrine-induced hypertensive emergency: treatment with Labetalol. Am J Emerg Med 1986; 4(2):141-142.
138	May CS, Pickup ME, Paterson JW. The acute and chronic bronchodilator effects of ephedrine in asthmatic patients. Br. J. Clin. Pharmac Jul 1975; 2: 533-537, Jul 1975.

139	McBride B, Karapanos A, Krudysz A, et al. Electrocardiographic and hemodynamic effects of a multicomponent dietary supplement containing ephedra and caffeine. JAMA Jan 14, 2004; 291(2): 216-221.
140	McGuffin M. Statement of Michael McGuffin. Hearings Before the FDA, Docket (Aug. 8, 2000).
141	McLaughlin, E.T., Bethea, L.H., and Wittig, H.J. Comparison of the bronchodilator effect of oral fenoterol and ephedrine in asthmatic children. Annals of Allergy 1982; 49:191-195.
142	Mitsuya H. Toxic psychosis due to ephedrine-containing antasthmatics-- report of three cases. Seishin Shinkeigaku Zasshi 1978; 80:155-168.
143	Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA. 2001;286(10):1195-1200.
144	Mokdad AH, Serdula MK, Dietz WH, et al. The spread of obesity epidemic in the United States, 1991-1998. JAMA 1999;282(16):1519-22.
145	Mokdad AH, Serdula MK, Dietz WH, et al.. The continuing epidemic of obesity in the United States. JAMA. 2000;284(13):1650-1.
146	Molnar D, Torok K, Erhardt E, et al. Safety and efficacy of treatment with an ephedrine/caffeine mixture. The first double-blind placebo-controlled pilot study in adolescents. International Journal of Obesity 2000; 24:1573-78.
147	Morgan, J.P. 1986. Phenylpropanolamine: A Critical Analysis of Reported Adverse Reactions and Overdosage. Jack K. Burgess, Inc., Fort Lee, NJ.
148	Moride Y, Haramburu F, Requejo AA, et al. Under-reporting of adverse drug reactions in general practice. Br J Clin Pharmacol 1997;43:177-81.
149	Mourand I, Ducrocq X, Lacour JC, Taillandier L, et al. Acute reversible cerebral arteritis associated with parenteral ephedrine use. Cerebrovasc Dis 1999; 9:355-357.
150	Mozayani, A. Analysis of Metabolife 356 Health Line Reports , August 2002 and January 2003.
151	Mozayani, A., Lopez A. Use, Misuse, and Abuse of Ephedrine & Pseudoephedrine. Society of Forensic Toxicologist Annual Meeting, New Orleans, LA, 2001.
152	Muittari, A. and Mattila, M.J. Objective and subjective assessment of ephedrine combinations in asthmatic outpatients. Annal of Clinical Research 1979; 11:87-89.
153	Muittari A, Mattila MJ, Patiala, J. Bronchodilator action of drug combinations in asthmatic patients: decloxizine, orciprenaline, and ephedrine. Annals of Allergy June 1969; 27:274-279.

154	Must A, Spadano J, Coakley EH, Fiels AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA 1999;282:1523-9.
155	Naik S, Freudenberger R. Ephedra-associated cardiomyopathy. The Annals of Pharmacology Mar 2004; 38:xxxx.
156	Nakayama T, Date C, Yokoyama T, et al. A 15.5-year follow-up study of stroke in a Japanese provincial city. The Shibata Study. Stroke 1997;28(1):45-52.
157	National College Athletics Association. NCAA study of substance use habits of college student-athletes (September 1997). available at URL: www.ncaa.org/library/research/htm#substance_use_habits. Accessed 6/25/2002.
158	NHTSA (National Highway Traffic Safety Administration). Federal motor vehicle standards; occupant crash protection. 1999. 49 CFR Parts 552, 571, 585, and 595. Docket No. NHTSA 99-6407; Notice 1, RIN 2127-AG70.
159	Nielsen B, Astrup A, Samuelsen P, et al. Effect of physical training on thermogenic responses to cold and ephedrine in obesity. Int J Obes 1993; 17:383-390.
160	Nightingale SL. From the Food and Drug Administration. JAMA 1992;268:1828
161	Oh RC. Exertional heatstroke in an infantry soldier taking ephedra-containing dietary supplements. Military Medicine 2003; 168:429-30.
162	Pederson K, Kuntz D, Garbe, G. Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year-old man, Canadian Journal of Cardiology 2001; 17(5):599-601.
163	Perrotta DM, Coody G, Culmo C. Adverse events associated with ephedrine-containing products: Texas, December 1993-September 1995. JAMA 1996; 276(21):1711-1712.
164	Pierson DJ, Hudson LD, Stark K, et al. Cardiopulmonary effects of terbutaline and a bronchodilator combination in chronic obstructive pulmonary disease. Chest Feb 1980; 77:176-182.
165	Robbers JE, Tyler VE. Tyler's Herbs of Choice. New York: The Haworth Herbal Press; 1999.
166	Roberge RJ, Hirani KH, Rowland PL, III, et al. Dextromethorphan- and pseudoephedrine-induced agitated psychosis and ataxia: Case report. J Emerg Med 1999; 17(2):1285-288.
167	Rosen RA. Angina associated with pseudoephedrine [letter]. Ann Emerg Med 1981; 10:230-231.
168	Rosenthal S: Chen R. The reporting sensitivities of two passive surveillance systems for vaccine adverse events. Am J Public Health 1995;85; 1706-9.
169	Salmon J and Nicholson D. DIC and rhabdomyolysis following pseudoephedrine overdose. Am J Emerg Med 1988; 6:545-546.

170	Schulman S. Addressing the potential risks associated with ephedra use: a review of recent efforts. Public health Rep. 2003 Nov.-Dec; 118(6):487-92.
171	Schneider RP. Ischemic colitis caused by decongestant? J Clin Gastroenterol 1995; 21:335-336.
172	Serup J. Exfoliative erythroderma after Elsinore pills and accidental provocation with ephedrine nose drops. Ugeskr Laeger 1981; 143:1660-1662.
173	Simi, W.W., and Miller, W.C. Clinical investigation of fenoterol, a new bronchodilataor, in asthma. J. Allergy Clin. Immunol Feb 1977; 59:178-181.
174	Sionneau, P. 1997. Dui Yao: The art of combining Chinese medicinals. World Scientific, Singapore. Blue Poppy Press, Boulder, CO
175	Smith TA. Phenethylamine and related compounds in plants. Phytochemistry 1977; 16:9-18.
176	Smith IG, Goulder MA. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract. 2001;50(6):505-12.
177	Soutullo CA, Cottingham EM and Keck PE, Jr. (1999). Psychosis associated with pseudoephedrine and dextromethorphan [letter]. JAm Acad Child Adolesc Psychiatry, 38: 1471-1472.
178	Stamler J, et al, Relationship to blood pressure of combinations of dietary micronutrients. Findings of the Multiple Risk Factor Intervention trial (MRFIT) Circulation 1996;94:2417-23.
179	Stephens MB, Olsen C. Ergogenic supplements and health risk behaviours. Journal of Family Practice 2001; 50(8):696-9.
180	Sternlo, J.E., Rettrup, A. and Sandin, R. Prophylactic i.m. ephedrine in bupivicaine spinal anaesthesia. Br J Anaesth 1995; 74:517-520.
181	Svendsen, T.L., Ingerslev, J., Mork, A. [Is Letigen contraindicated in hypertension? A double-blind placebo controlled multipractice study of Letigen administered to normotensive and adequately treated patients with hypersenitivity]. Ugeskr Laeger June 1998; 160:4073-5.
182	Tanaka T, Obha K, Kawaahara K, Sakai E. Comparison of the constituents of ephedra herbs from various countries on ephedrine type alkaloids. Natural Medicines. 1995;49:418-424.
183	Tang, D.H. 1996. Ephedra ('Ma huang') Clin Toxicol Rev 18(10).
184	Taylor M, FDA DHHS, Letter to James S. turner, Swankin and Turner, Washington, DC (Nov. 21, 1986).
185	Teutsch SM, Thacker SB. Planning a public health surveillance system. Epidemiological Bulletin: Pan American Health Organization 1995;16:1-6.

186	Thorvaldsen P, Davidsen M, Bronnum-Hansen H, et al. Stable stroke occurrence despite incidence reduction in an aging population: stroke trends in the Danish monitoring trends and determinants in cardiovascular disease (MONICA) population. Stroke 1999;30:2529-34.
187	Tinkelman, D.G., and Avner, S. Ephedrine therapy in asthmatic children. Clinical tolerance and absence of side effects. JAMA Feb 1977; 237:553-557.
188	Tomb RR, Lepoittevin JP, Espinassouze F, Heid E, and Foussereau. Systemic contact dermatitis from pseudoephedrine. Contact Dermatitis 1991; 24:86-88.
189	Tyler CW Jr, Last JM. Epidemiology. In: Public Health and Preventive Medicine. Wallace RB, ed. Stamford, CT: Appleton & Lange, pp. 5-31, 1998.
190	Vallerand A. Effects of ephedrine/xanthines on thermogenesis and cold tolerance. Int J Obes 1993; 17:S53-S56.
191	Varga, J., Jimenez, S.A., Uitto, J. l-Tryptophan and eosinophilia-myalgia syndrome: current understanding of the etiology and pathogenesis. J Investig Dermatol 1993;100:97S-105S.
192	Vega F, Rosales MJ, Esteve P, Morcillo R, Panizo C and Rodriguez M (1998). Histopathology of dermatitis due to pseudoephedrine. Allergy 1998; 53:218-220.
193	Vidal C, Prieto A, Perez-Can-al C and Armisen M. Nonpigmenting fixed drug eruption due to pseudoephedrine. Ann Allergy Asthma Immunol 1998; 80:309-310.
194	Wannamethee SG, Shaper AG, Whincup PH, Walker M, Characteristics of older men who lose weight intentionally or unintentionally., Am J Epidemiol. 2000 Apr 1;151(7):667-75.
195	Warner R, Lee A. Leber hereditary optic neuropathy associated with use of ephedra alkaloids. American Journal of Ophthalmology Dec 2002; 134(6):918-20.
196	Wettach GE. A mysterious blood pressure increase in a drilling naval reservist. Military Medicine 2002; 167(6):521-23.
197	White AD, Rosamond WD, Chambless LE, et al. Sex and race differences in short-term prognosis after acute coronary heart disease events: the Atherosclerosis Risk In Communities (ARIC) study. Am Heart J 1999;138:540-8.
198	Whittet HB, Veitch D. Ischaemic chest pain after abuse of a topical nasal vasoconstrictor. Br Med J 1989; 299:860.
199	Wilhelmsen L, Rosengren A, Johansson S, et al. Coronary heart disease attack rate, incidence and mortality 1975-1994 in Goteborg, Sweden. Eur Heart J 1997; 18:572-81.
200	Wirth A, Krause J. Long-term weight loss with sibutramine: a randomized controlled trial. JAMA. 2001;286(11):1331-9.
201	Wooltorton E, Sibbald B. Ephedra/ephedrine: cardiovascular and CNS effects. Canadian Medical Association Journal (June 14, 2001) at http:www.hc-sc.gc.ca/English/archives/warnings/2001/2001_67e.htm

202	World Health Organization. Controlling the global obesity epidemic. available at URL: http://www.who.int/nut/obs.htm. Accessed 6/20/2002.
203	Zwietering, P.J., et al., Arrhythmias in general practice: diagnostic value of patient characteristics, medical history and symptoms. Fam Pract 1998; 15(4):343-53